arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Neumora Therapeutics, Inc.

NMRA

$0.49 ▼ -0.09 (-15.05%) at close

5 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Neumora Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $80.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -152.3% ↘

FCF / Share $-1.26 ↘

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity 0.52

info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-236.93M

↑ +2.8% —

FCF / Share Free cash flow per share

$-1.26

↓ -10.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	5.2% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	57.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	24.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	2.8% Caution ↑ Caution Improving Year-over-year change in net income	-3.3% Weak Weak Year-over-year change in net income	-80.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-10.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	54.3% Excellent Excellent Year-over-year change in free cash flow	40.8% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-152.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-91.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	24.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-126.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-83.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-50.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-31.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-228.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1621%)	-84.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-666%)	-50.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-435%)	29.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+95%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Debt to Equity (x)	0.52x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-13%)	—	—	—	—
Interest Coverage (x)	-119.98x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-128.00M	$-142.15M	$-374.04M	$-240.94M	—
Debt / EBITDA (x)	-0.23x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-1.45	$-1.53	$-3.63	$-4.81	—
Free Cash Flow per Share (USD)	$-1.26	$-1.15	$-2.51	$-4.24	—
Book Value per Share (USD)	$0.60	$1.78	$2.95	$-13.70	—
Tangible Book Value per Share (USD)	$0.60	$1.78	$2.95	$-13.70	—
Basic Weighted Avg Shares (shares)	163.39M	159.38M	65.02M	27.21M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$158.09M	$284.17M	$453.17M	$364.26M	—
LT Debt (USD)	$54.53M	—	—	—	—
Total Equity (USD)	$103.87M	$287.06M	$469.08M	$-446.85M	$-325.22M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Depreciation Expense (USD)	$208.00K	$631.00K	$668.00K	$594.00K	—
Net Income, GAAP (USD)	$-236.93M	$-243.79M	$-235.93M	$-130.90M	—
Operating Cash Flow (USD)	$-206.44M	$-182.94M	$-163.28M	$-114.90M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters

Neumora Therapeutics, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NMRA with peers